Icon

Orenitram - (2.5 mg; Tablet, Extended Release)

Treprostinil United Therapeutic Corporation
2.5 mg; Tablet, Extended Release
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.
Yes
******* ** *** ***** ** **** **** ** **** ******* ’*** (**** **, ****), ’ *** (**** **, ****), ’*** (*** **, ****), ’ *** (*** **, ****), ’ *** (*** **, ****), ’*** (*** **, ****), ’ *** (*** **, ****),’ *** (*** *, ****) *** ’*** (*** **, ****) *** *** ************ *********. ****** *** ****** ** ** ****** **** ********** *** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** **, ****. (*****://**************.**********.***/***-**********/********-****-****-****-************.***) ****** ************ *********** *** ******** ***************, *** ***** **** ******* *** *************** ** ***** **, ****
Orenitram Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
*** ****** ******* ******* ******* ******* ******* *** ********* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** *** *, **** ******* ********* ******** ** *** **, ****
*** ****** ** \ ** *** **, **** ******* **** ** ** ****
  1. *** **, **** : * **** ** ***** .
  2. *** **, **** : ******* ******** ****** ************ ***** *** **** ** **** ******* ’*** (**** **, ****), ’ *** (**** **, ****), ’*** (*** **, ****), ’ *** (*** **, ****), ’ *** (*** **, ****), ’*** (*** **, ****), ’ *** (*** **, ****),’ *** (*** *, ****) *** ’*** (*** **, ****).
  3. *** **, **** : ****** ************* ***** * **** ******* ******* ** ******** ***** ** **.
  4. *** **, **** : ********** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** **, ****.
  5. *** *, **** : ****** ************* ***** * **** ******* *** ****************
  6. *** **, **** : ****** ************* ********* ********** **** *** ***************. ** ****** ** *** * **********.

Orenitram - (0.25, 1 mg; Tablet ER)

Treprostinil United Therapeutic Corporation
0.25, 1 mg; Tablet ER
Less Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
None None
None
No
****** ************* ***** * **** ******* *******. ********** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** **, ****. (*****://**************.**********.***/***-**********/********-****-****-****-************.***)
Orenitram Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** *** **, **** ******* ********* ******** ** *** **, ****
  1. *** **, **** : * **** ** *****.
  2. *** **, **** : ****** ************* ***** * **** ******* *******.
  3. *** **, **** : ********** ******* **** ******* ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** **, ****.

Orenitram - (0.125, 5 mg; Tablet ER)

Treprostinil United Therapeutic Corporation
0.125, 5 mg; Tablet ER
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
None
No
* **** ** ***** ** ******* *******. ********* ** *********'* *** ******, ******** *** ****** *** ******* ** *** ****. (*****://**************.**********.***/***-**********/********-****-****-****-************.***)
Orenitram Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
** *******
  1. *** **, **** : * **** ** ***** ** ******* *******.
  2. *** *, **** : ******* ******** ********* ******** *** *** *** ********* *** **** ********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.